VCM
VYGR icon

Versant Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Versant Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-617
Closed -$2.38K – 2860
2026
Q1 		$2.38K Sell
617
-402
-39% -$1.58K ﹤0.01% 2538
2025
Q4 		$4K Buy
+1,019
New +$4.51K ﹤0.01% 2325

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Versant Capital Management's VYGR Position: Q2 2026 in Review

Versant Capital Management sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 617 shares — an estimated $2.38K sold.

Versant Capital Management first reported a position in VYGR in Q4 2025 and held it in 2 quarters. The position peaked at $4K in Q4 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Versant Capital Management reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 617 Voyager Therapeutics shares in Q2 2026, an estimated $2.38K.
  • Versant Capital Management first reported a position in Voyager Therapeutics in Q4 2025 and held it in 2 quarters.
  • Versant Capital Management's Voyager Therapeutics position peaked at $4K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.